We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Evgen Pharma Plc | LSE:EVG | London | Ordinary Share | GB00BSVYN304 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.80 | 0.75 | 0.85 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 422k | -4.04M | -0.0147 | -0.54 | 2.2M |
Date | Subject | Author | Discuss |
---|---|---|---|
31/3/2022 09:38 | What's Evgen Pharam? | on target | |
31/3/2022 09:26 | New thread for discussion on Evgen Pharam. I will be updating the thread over today. The share price has fallen from placing price of 8p to 3.5p. Adequate cash to last 2-3 years and an updated website and presentation. Drugs in development include SFX-01 and others. | manual dexterity | |
31/3/2022 09:20 | Starting a new thread. for 2022. | manual dexterity | |
31/3/2022 09:18 | closed thread. | manual dexterity | |
29/3/2022 13:43 | From the Presentation : Recent Achievements mBC Commencement of pre-clinical collaboration with the University of Manchester and The Christie Hospital. Generate data to optimise positioning of SFX-01 in breast cancer treatment following promising Phase 2a clinical data. Out license market average $19m up front, $144m total, 10-14% royalty* Glioma Publication of powerful pre-clinical data including significant survival benefit, October 2021 Out licence market average $11m up front, $90m total, 8-12% royalty* Onc 3 Collaboration underway with a prestigious academic institution on a target relevant to solid tumours and blood cancers. Partner Sulforadex technology licence concluded with Juvenescence for nonpharmaceutical applications using naturally derived sulforaphane. $10.5m in milestones / options plus royalty. Market launch in 2023 FDA Orphan Drug designation achieved with FDA for malignant glioma, September 2021. * Source Global Data, Pre-clinical to Phase2 only, disclosed deal | manual dexterity | |
29/3/2022 08:53 | Thanks for posting that link MD. | clocktower | |
29/3/2022 07:57 | To add further, James Robert Kight is the largest shareholder and has constantly added to 12% and may go beyond. So I would not be surprised to see him add at all time lows. | manual dexterity | |
29/3/2022 07:49 | Yesterday's trade could be the end of the overhang. Certainly online limits have been slashed and cash available should last at least another 2 / 3 years. UPDATE PRESENTATION | manual dexterity | |
28/3/2022 13:51 | Good to see some decent volume anyway. Still cannot understand who was selling all those shares of late, without any TR-1's to follow. Surely not just PI's packing up and leaving? Ah well, wake me up if/when we revisit the 9p region. GLA. | lovewinshatelosses | |
28/3/2022 12:52 | Wonder if that 5M is from Juv-life? That would put a cat among the pigeons. We won't get a TR-1 just from that though as it's 'only' 1.8%. | on target | |
28/3/2022 11:09 | Any overhang there was has clearly been shifted and its not long before it will be back to 5p and if we get get more positive news the sky will be very blue. | clocktower | |
28/3/2022 10:35 | Somethings cooking with that 5mmn trade and volume way this morning. | clocktower | |
24/3/2022 22:30 | another one for the AIM 1p club...... | theonewhoknows2 | |
24/3/2022 21:29 | Presumably it is now at a level where cash and assets (excluding the directors) exceeds liabilities ( including directors) substantially. | bocker01 | |
24/3/2022 10:20 | Walbrook and fincap say no more !!! | amaretto1 | |
24/3/2022 10:07 | worked sale of 800000 gone through at 3p, ouch. Hopefully this has been dragging price a bit and can move forward now...some news would be good. | markth126 | |
23/3/2022 08:00 | Yep. Some decent inside buying (like 4D BOD did) should have been the minimum criteria to consider investing here as a PI...but I am a LTH and frankly did not apply the same criteria to my AIM investment strategy then as I do now. All that said, I still think we might have something worthwhile here, so I remain a holder - but not a happy one right now - unlike 4D at the time of print :) | lovewinshatelosses | |
22/3/2022 08:33 | Management want shooting....Total mkt destruction of a company value wise ....They came to mkt and fleeced share holders .... backed up with a ramp bridge working for their house broker.The red flag was NO monetary commitment by them !! Some one change my mind on these crooks .... | amaretto1 | |
21/3/2022 13:43 | Really turning out to be a dog with not an owner wanting it, as the slid continues. | clocktower | |
11/3/2022 16:21 | Not before time either. So oversold it was only a matter of time before we would see the start of a decent bounce. | clocktower | |
11/3/2022 15:55 | A few buyers this afternoon.. | on target | |
07/3/2022 16:38 | Such an expert !!The rats have left ...... | amaretto1 | |
07/3/2022 14:14 | Going by past performance, this announcement will just be the start of it. Expect more over the next week. Don't hold your breath though, they'll just regurgitate what's out there already but with added sparkle. | kingalf |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions